drugset / Trial / NCT04463680

Rifampin and the Contraceptive Implant

NCT04463680

NaSingle-groupOpen-labelBasic science

Summary

It is important for women taking rifampin to be aware if they are at greater risk of an unintended pregnancy while on the implant. An unintended pregnancy has many social, emotional, and financial impacts on women and society. Rifampin is also a Class C medication for pregnancy and could have potential negative effects on a developing fetus. Additionally, women considering rifampin for treatment of LTBI face additional risks with an unintended pregnancy, making the reliability of contraception even more important for these women. The results of this study can directly inform counseling on a national and international basis for women who use the contraceptive implant and are considering their treatment options for LTBI.

Timeline

Start
2020-09-23
Primary completion
2022-02-22
Completion
2022-02-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifampin Small molecule 600 mg

Indications